Navigation Links
Alexza Pharmaceuticals Provides Regulatory Update for AZ-004 (Staccato® Loxapine)
Date:12/7/2010

is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. The drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. (Click here to see an animation of how the Staccato system works.)

AZ-004 (Staccato loxapine) is Alexza's lead program, which is being developed for the rapid treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials and submitted the AZ-004 NDA in December 2009.  In October 2010, the Company received a CRL from the FDA, regarding its NDA for AZ-004.  A CRL is issued by FDA's Center for Drug Evaluation and Research indicating that the NDA review cycle is complete and the application is not ready for approval in its present form.  The Company is currently evaluating the FDA's comments in the CRL and has scheduled a meeting with the FDA in December 2010 to discuss the CRL.

For more information about Alexza, the Staccato technology or the Company's development programs, please visit www.alexza.com.

Safe Harbor Statement

This press release includes forward-looking statements regarding the development and safety of the Company's product candidates and technologies.  Any statement describing the Company's expectations or beliefs is a forward-looking statement, as defined in the Private Se
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... Bridgewater, New Jersey location received ... Administration (FDA) relating to an inspection in June 2014 ... injectable, which was divested to Galderma S.A. in July ... contract manufacturers (rather than Valeant,s own internal manufacturing) with ...
(Date:9/30/2014)... -- The Eastern European medical device industry is in ... as new medical-device manufacturers are constantly trying to penetrate ... to reduce the cost incurred for placing their products ... effective means to achieve this target. This research service ... and provides profiles of key distributors in ...
(Date:9/30/2014)... , Sept. 30, 2014   Decision ... patient-level claims data, anemic chronic kidney disease non-dialysis ... erythropoiesis-stimulating agent (ESA) medication. In addition, one-year persistency ... Other key findings from the ... An Analysis of Erythropoiesis Stimulating Agents in Late ...
Breaking Medicine Technology:Valeant Pharmaceuticals' Bridgewater Location Receives Warning Letter From FDA 2Medical Technologies Distributor Profiles in Eastern Europe 2Medical Technologies Distributor Profiles in Eastern Europe 3Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 2Persistency is Low for Late-Stage Anemic CKD Non-Dialysis Patients Treated with Erythropoiesis-Stimulating Agents 3
... On Friday, April 20, 2012, at 8:30 a.m. Eastern/2:30 ... Inc.,s (CTI) (NASDAQ and MTA: CTIC) management team will ... first quarter achievements and financial results. ... Central European/5:30 a.m. Pacific Time 1-800-762-8779 (US Participants) ...
... 2012  Watson Pharmaceuticals, Inc. (NYSE: WPI ) ... version of FORTAMET® (metformin hydrochloride extended-release tablets) as part ... the product today. FORTAMET® is indicated as an adjunct ... patients 17 years of age or older. ...
Cached Medicine Technology:Watson Launches Generic FORTAMET(R) 2
(Date:9/30/2014)... Antonio, TX (PRWEB) September 30, 2014 ... September, the Editorial Board of Living with a ... that sheds light on hematological disorders as disabling conditions. ... SSA requires more than a diagnosis to establish a ... cell, chronic thrombocytomenia, myelofibrosis, hereditary telangiectasia, coagulation defects, polycythemia ...
(Date:9/30/2014)... (PRWEB) September 30, 2014 Catalent ... of advanced delivery technologies and development solutions for ... a full agenda for the 25th Annual CPhI ... from October 6th to 9th. , Catalent is ... capability expansions during the show, including its facilities ...
(Date:9/30/2014)... Jiwa Law Corporation, a personal injury law ... now be offering free consultation for personal injury claims of ... firm for the first time to meet the Vancouver ICBC ... opportunity to understand what their rights are. The experts at ... to explain to them what the law firm can do ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 ... its first “crowdfunding” campaign through GoFundMe. The campaign, which ... was for a portion of the funds necessary to ... bus for the Stockton Unified School District (SUSD). The ... will provide a portion of the funds necessary for ...
(Date:9/30/2014)... Coast Dental and Orthodontics is ... practice, located at 1010 Shaw Avenue in Clovis, CA. ... services , and specialty dental care including orthodontics, endodontics, ... and convenient dental care, our Clovis dentists also strive ... Coast Dental at 559-777-6113 to schedule an appointment. , ...
Breaking Medicine News(10 mins):Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 2Health News:Living with a Disability Magazine Marks National Sickle Cell Health Month with New Article on Hematological Disorders 3Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 2Health News:Catalent Showcases Advanced Technologies and Supply Capabilities at CPhI Worldwide Conference and Exhibition 3Health News:Jiwa Law Corporation Now Offers Personal Injury Consultation Without Any Charge 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 2Health News:ADOMANI Raises More Than 100,000 Dollars Through GoFundMe to Convert a School Bus 3Health News:Coast Dental Clovis Celebrates Grand Opening 2Health News:Coast Dental Clovis Celebrates Grand Opening 3
... WHO has revealed that Africa's TB crisis has its origin ... of the two million people who die from TB every ... nurse at the African Medical and Research Foundation (AMREF) clinic ... who succumbed to TB were also infected with HIV. According ...
... study conducted by Columbia University Medical Center has ... in osteoarthritis, could be effective// in the treatment ... drug treatment with Cox-2 inhibitors or surgery was ... chronic shoulder pain. ,Approximately 1.5 million ...
... to World Health Organization (WHO), two fresh cases of ... from Mudug region//, in southern Somalia and northeastern Somalia ... to neighbouring countries. ,The cases also threaten ... the outbreak which has affected a total of 199 ...
... shoulder pain were left with only two options previously, either ... the safety concerns surrounding Vioxx and other Cox-2 inhibitors were ... has found that sodium hyaluronate, a drug approved by FDA ... for treating the shoulder pain. ,The study was ...
... Transesophageal echocardiography (TEE) is a recent progress in echocardiography ... procedure entails the insertion of a // probe into ... off the heart and help in enabling a motion ... echocardiogram. , ,These detailed images are capable of ...
... and Drug Administration (FDA) approved asthma Flovent HFA for kids ... a reformulation of Flovent that uses the more environmentally friendly ... the canister. ,It is an inhaled corticosteroid that ... , The medication initially was approved by the FDA ...
Cached Medicine News:Health News:Sodium Hyaluronate Shows Promise In Treatment Of Shoulder Pain 2Health News:New Drug For Treating Chronic Shoulder Pain 2Health News:New Drug For Treating Chronic Shoulder Pain 3
This adjustable-volume digital micropipet is used to accurately measure and transfer small solution volumes in the 20-200 microliter range....
... and density. Proven ergonomic design reduces hand fatigue, prevents injury. Dry seal ... 20-200 ... 1.0~2.0 Imprecision(%) ... 1 Dimensions: ...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,411-9) or contact custom...
Pipetman P is a fully adjustable, air-displacement pipette with the selected volume shown on a digital indicator (volumeter). Eight models cover the full range of volumes from 0.2 L to 10 mL....
Medicine Products: